首页> 外文OA文献 >Faculty Opinions recommendation of Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

【2h】

Faculty Opinions recommendation of Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

机译：教师意见建议BGJ398，成纤维细胞生长因子受体1-3抑制剂在先前治疗的先进尿路上皮癌的患者中推荐疗效，具有FGFR3改变。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Matthew Milowsky;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations [J] . Pal Sumanta K., Rosenberg Jonathan E., Hoffman-Censits Jean H., Cancer discovery. . 2018,第7期

机译：BGJ398，成纤维细胞生长因子受体1-3抑制剂的功效，以先前治疗的先进尿路上皮癌，FGFR3改变
2. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose Escalation and Dose-Expansion Study (vol 35, pg 157, 2017) [J] . Burris Howard A. Journal of Clinical Oncology . 2019,第4期

机译：评价BGJ398，一种成纤维细胞生长因子受体1-3激酶抑制剂，患者患有成纤维细胞生长因子受体的遗传改变的患者：全球阶段I，剂量升级和剂量膨胀研究的结果（Vol 35，PG 157 ，2017）
3. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study (vol 35, pg 157, 2017) [J] . Nogova Journal of Clinical Oncology . 2017,第8期

机译：评价BGJ398，一种成纤维细胞生长因子受体1-3激酶抑制剂，患有成纤维细胞生长因子受体的遗传改变的患者：全球阶段I，剂量升级和剂量扩展研究的结果（Vol 35，PG 157,2017）
4. The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses Proliferation and Invasion of Human Oral Squamous Carcinoma Cells via p53 Independent and MMP, uPAR Dependent Mechanism [C] . EUN JU LEE, JIN HA WHANG, NAM KYEONG JEON, Meeting on Cell Signaling World: Signal Transduction Pathways as Therapeutic Targets . 2007

机译：表皮生长因子受体酪氨酸激酶抑制剂ZD1839（Iressa）通过独立于p53和MMP，uPAR依赖性机制抑制人口腔鳞状细胞癌细胞的增殖和侵袭
5. Mutation, SNP and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. [D] . Onwuazor, Obiageli Nneka. 2003

机译：150名新诊断的多发性骨髓瘤患者的成纤维细胞生长因子受体3（FGFR3）的突变，SNP和同工型分析。
6. Efficacy of BGJ398 a fibroblast growth factor receptor 1–3 inhibitor in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations [O] . Sumanta K. Pal, Jonathan E. Rosenberg, Jean H. Hoffman-Censits, -1

机译：BGJ398（一种成纤维细胞生长因子受体1-3抑制剂）在先前治疗的具有FGFR3改变的晚期尿路上皮癌患者中的疗效
7. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations [O] . Sumanta K. Pal, Jonathan E. Rosenberg, Jean H. Hoffman-Censits, 2018

机译：BGJ398，成纤维细胞生长因子受体1-3抑制剂的功效，以先前治疗的先进尿路上皮癌，FGFR3改变

Faculty Opinions recommendation of Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

著录项

相似文献

相关主题

期刊订阅